Ross\Johnson & Associates’s AbbVie ABBV Stock Holding History

Ross\Johnson & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.26K	Sell	15 -2	-12%	-$444	0.06%	58
2025 Q4	$3.88K	Buy	17 +2	+13%	+$456	0.07%	55
2025 Q3	$3.47K	Hold	15	–	–	0.07%	58
2025 Q2	$2.78K	Sell	15 -5	-25%	-$929	0.06%	58
2025 Q1	$4.19K	Buy	20 +9	+82%	+$1.75K	0.07%	100
2024 Q4	$1.96K	Buy	+11	New	+$2.02K	0.05%	70

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ross\Johnson & Associates's ABBV Position: Q1 2026 in Review

Ross\Johnson & Associates reduced its AbbVie (ABBV) stake by 12% in Q1 2026, selling an estimated $444 and leaving 15 shares worth $3.26K. The position accounts for 0.06% of the portfolio, ranked #58.

Ross\Johnson & Associates first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.19K in Q1 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ross\Johnson & Associates held 15 shares of AbbVie worth $3.26K as of Q1 2026.
Ross\Johnson & Associates sold 2 AbbVie shares in Q1 2026, an estimated $444.
AbbVie made up 0.06% of Ross\Johnson & Associates's portfolio in Q1 2026, its #58 holding.
Ross\Johnson & Associates first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
Ross\Johnson & Associates's AbbVie position peaked at $4.19K in Q1 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.